A5038263029- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Single-cell and spatial transcriptomics
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Renal and related cancers
- MicroRNA in disease regulation
- RNA modifications and cancer
Vanderbilt University
2022-2024
Clonal hematopoiesis (CH) is an age-associated phenomenon that increases the risk of hematologic malignancy and cardiovascular disease. CH thought to enhance disease through inflammation in peripheral blood.1 Here, we profile blood gene expression 66 968 single cells from a cohort 17 patients with 7 controls. Using novel mitochondrial DNA barcoding approach, were able identify separately compare mutant Tet methylcytosine dioxygenase 2 (TET2) methyltransferase 3A (DNMT3A) nonmutant...
Abstract Clonal evolution in myelodysplastic syndrome (MDS) can result clinical progression and secondary acute myeloid leukemia (sAML). To dissect changes clonal architecture associated with this progression, we performed single-cell genotyping of paired MDS sAML samples from 18 patients. Analysis genotypes revealed patient-specific enabled the assessment mutational cooccurrence. We discovered that proceed via distinct patterns, classified as static or dynamic, dynamic architectures having...
Abstract Clonal hematopoiesis (CH) is an age-associated phenomenon that increases risk for hematologic malignancy and cardiovascular disease. CH thought to enhance disease through inflammation in the peripheral blood 1 . Here, we profile gene expression 66,968 single cells from a cohort of 17 patients 7 controls. Using novel mitochondrial DNA barcoding approach, were able identify separately compare mutant TET2 DNMT3A non-mutant counterparts. We discovered vast majority mutated myeloid...
Introduction: Clonal hematopoiesis of indeterminate potential (CHIP) results from a clonal expansion hematopoietic stem cells due to somatic mutations in genes such as DNMT3A or TET2. Patients with CHIP have poor cardiovascular outcomes. TET2 clones that make up >20% blood increases risk. Whether mutated confer risk directly through polarizing other is presently unknown prior work has been unable simultaneously resolve mutational status and transcriptome an individual cell. Methods: We...